Health ❯ Healthcare

Pharmaceuticals

Drug Development Drug Approval Clinical Trials Drug Safety Drug Pricing Weight Loss Weight Loss Drugs Cancer Treatment Drug Regulation Medications

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

The all-cash deal gives the Italian group a U.S. foothold to scale a Brain Health–focused rare-disease platform.

Gilead Lifts 2026 Sales Outlook, Warns of Loss on $11.5 Billion Deal Charge

Novartis Breaks Ground on Texas Plant to Speed Radioligand Cancer Drug Delivery

NEJM Study and FDA Access Advance Daraxonrasib for Pancreatic Cancer

White House Projects $529 Billion in Savings From Trump’s MFN Drug Pricing Plan

Doctors Reject Ivermectin Claims as Hantavirus Cruise Outbreak Kills Three

Analysts Lift Eli Lilly Targets After Blowout Quarter and Foundayo Debut

FDA Chief Makary Faces Intensifying Pressure as Vape Approvals and Staff Shake-Up Fuel Scrutiny

Stories older than 24h

Novo Nordisk Lifts Outlook After Wegovy Pill Fuels Q1 Beat

Pfizer Beats Q1 Forecasts as Newer Drugs Offset COVID Slide

FDA Approves Langlara as Interchangeable Biosimilar to Lantus

DOJ Moves State-Licensed Medical Marijuana to Schedule III Ahead of June DEA Hearing

Nuvation Bio Reports Q1 Growth as Iptrozy Moves Earlier in ROS1 Lung Cancer Care

Axsome Reports 57% Q1 Sales Jump as FDA Clears Auvelity for Alzheimer’s Agitation

Pfizer Tops Q1 Forecasts on Eliquis Strength, Reaffirms 2026 Outlook

Nektar Investors Face May 5 Deadline in Securities Suit Over REZOLVE-AA Trial Claims

Appeals Court Blocks Mailed Abortion Pills, Reinstates In-Person Pickup Nationwide

FDA Authorizes Early Access to Daraxonrasib for Pancreatic Cancer Patients

FDA Proposes Blocking Bulk Compounding of GLP-1 Drugs by Outsourcing Facilities

FDA Approves Auvelity as First Non‑Antipsychotic for Alzheimer’s Agitation